Loading...
Loading...
MDXH| Name | Value |
|---|---|
| Revenues | 19.8M |
| Cost of Revenue | 8.9M |
| Gross Profit | 10.9M |
| Operating Expense | 17.6M |
| Operating I/L | -6.6M |
| Other Income/Expense | -1.9M |
| Interest Income | 1.9M |
| Pretax | -8.5M |
| Income Tax Expense | 1.9M |
| Net Income/Loss | -8.5M |
MDxHealth SA is a precision diagnostics company that offers urologic solutions, specializing in novel prostate cancer genomic testing. Its flagship products, SelectMDx and ConfirmMDx, are non-invasive urine and epigenetic tests, respectively, designed to aid physicians in identifying clinically significant prostate cancer while reducing the need for invasive procedures. By providing these innovative diagnostic solutions, MDxHealth generates revenue from the sale of its testing services and related products to healthcare providers and institutions.
